Results 131 to 140 of about 7,486 (163)

Anti-CD20 associated enterovirus meningoencephalitis: A narrative review with two illustrative cases. [PDF]

Mult Scler J Exp Transl Clin
Mahajan KR, Bittner F, Willis MA, Isada C, Bermel R, Fox RJ, Lee J, Kunchok A.   +7 more
europepmc   +1 more source

Long-Term Clinical and Psychological Efficacy and Safety of Ocrelizumab in People With Multiple Sclerosis: A Real-World Longitudinal Study. [PDF]

Health Sci Rep
Jafari M, Yazdan Panah M, Vaheb S, Adibi I, Ashtari F, Shaygannejad V, Zabeti A, Mirmosayyeb O.   +7 more
europepmc   +1 more source

Investigating the role of serum IL-6 in predicting outcomes of b-cell depleting therapy in multiple sclerosis: a retrospective cohort study. [PDF]

BMC Neurol
Kölsche T, Hagler R, Huntemann N, Masanneck L, Müller M, Kutsojannis BJ, Boeckers JM, Kirschner P, Schulze-Bosse K, Aktas O, Meuth SG, Ruck T, Pawlitzki M.   +12 more
europepmc   +1 more source

Babesiosis at ultra-low parasitemia presenting as secondary hemophagocytic lymphohistiocytosis in a patient on B cell-depleting therapy. [PDF]

ASM Case Rep
Toumeh N, Bisono Garcia BS, Norrie FC, Thoendel MJ, Ranganath N.   +4 more
europepmc   +1 more source

Comparative Effectiveness and Safety of Rituximab Versus Ocrelizumab in Relapsing-Remitting Multiple Sclerosis: A Finnish Population-Based Matched Cohort Study. [PDF]

Eur J Neurol
Savolainen M, Soilu-Hänninen M, Nurmi H, Viitala M, Tienari P, Atula S, Laakso SM.   +6 more
europepmc   +1 more source

Dermatological and gastrointestinal adverse reactions in ocrelizumab treated patients with multiple sclerosis: a case series. [PDF]

Front Immunol
Höpner LK, Marschall E, Schindler P, Frauendorf V, Böhmig M, Rakers F, Karimi D, Faber C, Ruprecht K, Otto C.   +9 more
europepmc   +1 more source

Reply to "Comparative Safety Profiles of Ocrelizumab and Rituximab in Multiple Sclerosis Treatment Using Real-World Evidence". [PDF]

Ann Neurol
Cerono G, Cree BAC, Hauser SL, Baranzini SE.   +3 more
europepmc   +1 more source

Real-world comparison of anti-CD20 therapies: efficacy, infections, and immune profiles in a German cohort. [PDF]

Front Immunol
Stögbauer J, Bewarder M, Groß L, Thurner L, Fassbender K, Urschel R, Høgestøl EA, Nygaard GO, Harbo HF, Stüve O, Pawlitzki M, Meuth SG, Sester M, Groppa S, Fousse M.   +14 more
europepmc   +1 more source

Ocrelizumab in early relapsing-remitting multiple sclerosis: first interim analysis of the MUSPO Italian prospective cohort. [PDF]

J Neurol
Filippi M, D'Amico E, Brescia Morra V, Zanetta C, Zanghì A, Di Filippo PS, Longobardi E, Colombo E, Mirabella M, Conte A, Tomassini V, Masini C, Perosino V, Tortorella P, Rocca MA, MUPSO Study Group.   +15 more
europepmc   +1 more source

From measurement to biomarker trajectories: platform-agnostic Z score analysis of serum NfL and GFAP in ocrelizumab-treated multiple sclerosis. [PDF]

J Neurol
Inojosa H, Masanneck L, Akgün K, Hagler R, Meuth SG, Otto C, Schindler P, Schulze-Bosse K, Kuhle J, Benkert P, Ruprecht K, Pawlitzki M, Ziemssen T.   +12 more
europepmc   +1 more source